Dear Editor,
Cell replacement therapy holds great therapeutic promise towards restoring tissue homeostasis. However, aging-associated functional decay and neoplastic transformation following transplantation must be overcome before cell therapies can be effectively and safely implemented in the clinical settings [1] [2] [3] [4] . This goal can theoretically be achieved by developing enhancement strategies towards endowing stem cells with more robust regenerative capacities and concomitantly, a reduced risk for tumorigenesis [5, 6] . Here, we provide an experimental and conceptual strategy on how to genetically engineer superior and safer stem cells.
We first aimed to identify and manipulate pathways or key genes able to repress cellular aging. To this end, we screened several gero-protective chemicals using Werner Syndrome (WS, WRN-deficient) human mesenchymal stem cell (hMSC) aging model [7] . We found Oltipraz, Metformin, and Resveratrol at indicated concentrations stimulated the proliferation of pre-senescent WS hMSCs (Supplementary information, Figure S1A ). Interestingly, these three chemicals are all known activators of the nuclear factor erythroid-2-like 2 (NRF2) pathway (Supplementary information, Figure S1B ). In addition, the protein abundance of NRF2 was decreased in WS or replicative senescent hMSCs (Supplementary information, Figure S1C ). These raise the possibility of enhancing NRF2 activity to augment the function and lifespan of hMSCs.
To activate NRF2 in a stable and controllable manner while retaining NRF2's native biological function with minimal genomic change, we focused on generating a single-nucleotide variation (A245G) in the NRF2 locus, which results in a glutamic acid to glycine switch at amino acid 82 of the NRF2 protein, and is supposed to lead to NRF2 stabilization and transcriptional activation of its target genes. We performed homologous recombination-based gene editing using helper-dependent adenoviral vector (HDAdV) [7] in WT human embryonic stem cells (ESCs) (NRF2 +/+ hESCs) and generated homozygous NRF2 A245G ESC lines (NRF2 AG/AG hESCs) ( Figure 1A and Supplementary information, Figure S2A and S2B). NRF2 AG/AG hESCs exhibited features of typical human primed state pluripotent stem cells (Supplementary information, Figure S2C and S2D) and were subsequently differentiated into hMSCs (Supplementary information, Figure S3A and S3B). In NRF2 AG/AG hMSCs, we found the endogenous NRF2 protein level was upregulated with more enrichment in the nucleus, which was accompanied by elevated NRF2 transcriptional activity ( Figure  1B and Supplementary information, Figure S3C -S3F). Importantly, genomic integrity was preserved after gene editing and differentiation procedures (Supplementary information, Figure S3G and S3H).
We next tested whether NRF2 enhancement is sufficient to counteract cellular senescence. Upon serial passaging, NRF2 +/+ hMSCs ceased growth after passage 10 (P10), whereas NRF2 AG/AG hMSCs maintained a robust proliferation until P19 ( Figure 1C and Supplementary information, Figure S4A and S4B). In contrast to NRF2 +/+ hMSCs, which exhibited progressive senescence, significantly lower percentages of senescence-associated (SA)-β-gal-positive cells and lower expression of senescence-associated genes (p16 Ink4a and p21 Waf1 ) were observed in NRF2 AG/AG hMSCs ( Figure 1D and Supplementary information, Figure S4C -S4E).
In line with NRF2's role in anti-oxidation, we observed lower basal ROS levels and fewer oxidative byproducts in NRF2 AG/AG hMSCs even after extensive passaging (Supplementary information, Figure S4F -S4H). Lowered ROS levels conferred by engineered NRF2 also alleviated senescence-associated defects in the nuclear envelope (NE) and in the (epi-)genome (Supplementary information, Figure S5 ). Similarly, human vascular endothelial cells (hVECs) [8] derived from NRF2 AG/AG hESCs exhibited substantial resistance to oxidative stress (Supplementary information, Figure S6 ). Together, these observations indicate that genetic activation of endogenous NRF2 helps alleviate aging-associated oxidative stress and subsequent cellular damage.
Moreover, we demonstrated this gene-editing strategy could elicit a therapeutic effect in the WS background. Genetic enhancement of NRF2 in WS hMSCs increased Figure S7 ). To understand the molecular mechanism by which genetic manipulation of NRF2 antagonizes cellular senescence in hMSCs, we performed RNA sequencing (RNA-seq) analysis (Supplementary information, Figure  S8A-S8D) . In P5 hMSCs, 36 upregulated (NRF2 AG/AG vs NRF2 +/+ > 1.5) NRF2-responsive cytoprotective genes were identified ( Figure 1E ). The upregulated genes were involved in stress response, cell viability, and cell proliferation (Supplementary information, Figure S8E ), consistent with the stress resistance and improved survival and proliferation observed in NRF2 AG/AG hMSCs. In P11 hMSCs, ~15% (159/1 090) of the upregulated genes were involved in cell cycle regulation (Supplementary information, Figure S8F ), in line with the sustained proliferation of NRF2 AG/AG hMSCs. Expression of over 50 DNA damage repair genes, NE protein-encoding genes and chromosome organization-associated genes was largely maintained in NRF2 AG/AG hMSCs at P11 (Supplementary information, Figure S9A and S9B), consistent with well-preserved DNA damage repair systems and nuclear architecture in NRF2 AG/AG hMSCs. In addition, transcriptomic analysis revealed less pronounced transcriptional changes in NRF2 AG/AG hMSCs during passaging (Supplementary information, Figure S9C and S9D).
To determine whether these genetically enhanced stem (GES) cells would confer better survival, engraftment and injury repair in vivo, we first implanted luciferase-labeled hMSCs into the muscle of nude mice [7, 8] . As expected, compared to WT hMSCs, NRF2 AG/AG hMSCs exhibited slower in vivo decay after transplantation (Supplementary information, Figure S10A ). Next, we utilized a well-established hind-limb ischemia murine model to evaluate the in vivo regenerative capacity of hMSCs [9] . After ligation of the femoral artery, blood perfusion of the left hind limb was reduced to about 10% that of the right hind limb in all mice examined ( Figure 1F-1G) . When compared to mice receiving WT hMSCs, a significantly faster blood flow recovery was observed in mice receiving NRF2 AG/AG hMSCs starting from day 8. In addition, we identified the presence of more human vascular endothelial and smooth muscle cells in NRF2 AG/AG hMSCs-implanted muscles ( Figure 1F-1G and Supplementary information, Figure S10B and S10C). These data indicate that edited hMSCs are superior to WT hMSCs in repairing tissue damage in vivo.
Oncogenic transformation of genetically modified cells constitutes a major safety concern [4] . Continuous monitoring for 8 months after NRF2 AG/AG hMSCs transplantation did not indicate any sign of tumor formation in immunodeficient mice (Supplementary information, Figure S11A ), demonstrating that tumor susceptibility was not elevated in NRF2 AG/AG hMSCs. However, it is still possible that NRF2 AG/AG hMSCs are susceptible to tumorigenic transformation in the presence of strong oncogenic insults. To examine this possibility, we adopted a reported in vitro MSC transformation system [10] Finally, we observed that the implantation of genetically edited hESCs (NRF2 AG/AG hESCs) resulted in the generation of much smaller teratomas in vivo ( Figure 1I ), supporting a possibility that even if residual undifferentiated NRF2 AG/AG hESCs are present in their MSC derivatives, the teratoma-forming ability of these cells are minimalized. This will pose less risk for teratoma formation, which is a major concern for cell replacement therapies using hESC derivatives.
In conclusion, our study provides an experimental proof-of-concept that recoding a single nucleotide within NRF2 gene endows cultured hMSCs with enhanced self-renewal ability, increased stress resistance, delayed cellular senescence and functional decay, better engraftment efficiency and functional regeneration in vivo, as well as greater resistance to oncogenic transformation, and thereby allows for the generation of superior and safer GES cells for regenerative medicine therapies (Supplementary information, Figure S14 ).
